Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Challenges in the diagnosis and treatment of juvenile systemic sclerosis

Nature Reviews Rheumatology volume 7, pages 676–680 (2011)Cite this article

Subjects

Abstract

During the past 10 years, descriptions of large registries of children with juvenile systemic sclerosis (jSSc) have improved our knowledge of this disease. jSSc differs from the adult disease in presentation as well as disease course. Two courses of disease have been described: a rapidly progressive and fatal illness with cardiac involvement; and, more commonly, a chronic course with less overall mortality. Subclinical disease, especially cardiac and pulmonary disease, should be specifically sought and appropriately monitored, particularly in the first years of disease. Use of screening pulmonary function tests and high-resolution CT increases the chance of detecting interstitial lung disease. Close attention needs to be paid to cardiac health, with improved understanding of the specific causes of death to aid in the development of preventive measures. Therapies that best balance risks and benefits are likely to differ between children and adults. Given the relative rarity of jSSc, pediatric trials will require multinational collaborative efforts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Severe digital insufficiency ulcers with differing degrees of healing from severe Raynaud phenomenon in a child with systemic scleroderma.
Figure 2

Similar content being viewed by others

References

  1. Zulian, F. et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45, 614–620 (2006).

    Article  CAS  Google Scholar 

  2. Foeldvari, I. et al. Favourable outcome in 135 children with systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 39, 556–559 (2000).

    Article  CAS  Google Scholar 

  3. Martini, G. et al. Systemic sclerosis in childhood: clinical and immunological features of 153 patients in an international database. Arthritis Rheum. 54, 3971–3978 (2006).

    Article  CAS  Google Scholar 

  4. Scalapino, K. et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J. Rheumatol. 33, 1004–1013 (2006).

    PubMed  Google Scholar 

  5. Zulian, F. et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 57, 203–212 (2007).

    Article  Google Scholar 

  6. Hunzelmann, N. et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 47, 1185–1192 (2008).

    Article  CAS  Google Scholar 

  7. Foeldvari, I. & Wierk, A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford) 45, 76–78 (2006).

    Article  CAS  Google Scholar 

  8. Leroy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).

    CAS  PubMed  Google Scholar 

  9. Nigrovic, P. A., Fuhlbrigge, R. C. & Sundel, R. P. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 111, 715–721 (2003).

    Article  Google Scholar 

  10. Dolezalova, P., Young, S. P., Bacon, P. A. & Southwood, T. R. Nailfold capillary microscopy in healthy children and in childhood rheumatic disease: a prospective single blind observational study. Ann. Rheum. Dis. 62, 444–449 (2003).

    Article  CAS  Google Scholar 

  11. Silver, R. M., Miller, K. S., Kinsella, M. B., Smith, E. A. & Schabel, S. I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 88, 470–476 (1990).

    Article  CAS  Google Scholar 

  12. Garty, B. Z. et al. Pulmonary function in children with progressive systemic sclerosis. Pediatrics 88, 1161–1167 (1991).

    CAS  PubMed  Google Scholar 

  13. Seely, J. M., Jones, L. T., Wallace, C., Sherry, D. & Effmann, E. L. Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am. J. Roentgenol. 170, 691–697 (1998).

    Article  CAS  Google Scholar 

  14. Panigada, S. et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr. Pulmonol. 44, 1226–1234 (2009).

    Article  Google Scholar 

  15. BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am. Rev. Respir. Dis. 141, S169–S202 (1990).

  16. Witt, C. et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann. Rheum. Dis. 58, 635–640 (1999).

    Article  CAS  Google Scholar 

  17. Strange, C. et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am. J. Respir. Crit. Care Med. 177, 91–98 (2008).

    Article  CAS  Google Scholar 

  18. Galie, N. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34, 1219–1263 (2009).

    Article  CAS  Google Scholar 

  19. Williams, M. H. et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J. 27, 1485–1494 (2006).

    Article  CAS  Google Scholar 

  20. Meune, C., Vignaux, O., Kahan, A. & Allanore, Y. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch. Cardiovasc. Dis. 103, 46–52 (2010).

    Article  Google Scholar 

  21. Martini, G. et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford) 48, 119–122 (2009).

    Article  CAS  Google Scholar 

  22. Barst, R. J., Ertel, S. I., Beghetti, M. & Ivy, D. D. Pulmonary arterial hypertension: a comparison between children and adults. Eur. Respir. J. 37, 665–677 (2011).

    Article  CAS  Google Scholar 

  23. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620–628 (2009).

    Article  CAS  Google Scholar 

  24. Tissot, C., Ivy, D. D. & Beghetti, M. Medical therapy for pediatric pulmonary arterial hypertension. J. Pediatr. 157, 528–532 (2010).

    Article  Google Scholar 

  25. Wozniak, J. et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. J. Rheumatol. 36, 191–196 (2009).

    Article  Google Scholar 

  26. Sánchez-Román, J. et al. Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography. Rheumatology (Oxford) 47 (Suppl. 5), v33–v35 (2008).

    Article  Google Scholar 

  27. Bussone, G., Bérezné, A., Pestre, V., Guillevin, L. & Mouthon, L. The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr. Rheumatol. Rep. 13, 37–43 (2011).

    Article  Google Scholar 

  28. Hamaguchi, Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J. Dermatol. 37, 42–53 (2010).

    Article  CAS  Google Scholar 

  29. Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).

    Article  CAS  Google Scholar 

  30. Au, K., Khanna, D., Clements, P. J., Furst, D. E. & Tashkin, D. P. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr. Rheumatol. Rep. 11, 111–119 (2009).

    Article  CAS  Google Scholar 

  31. Khanna, D., Furst, D. E., Clements, P. J., Tashkin, D. P. & Eckman, M. H. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med. Decis. Making 28, 926–937 (2008).

    Article  Google Scholar 

  32. Su, R. et al. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. J. Rheumatol. 38, 693–711 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University School of Medicine, Box 3212, Duke University Medical Center, Durham, 27710, NC, USA

    C. Egla Rabinovich

Authors
  1. C. Egla Rabinovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabinovich, C. Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol 7, 676–680 (2011). https://doi.org/10.1038/nrrheum.2011.148

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2011.148

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing